Surgical prophylaxis for inheritable malignant diseases: Breast cancer and endocrine disease

American Surgeon

Volumn 75, Issue 7, 2009, Pages 529-536

  Benns, Matthew V ^a   Tammy, L U K ^a   Scoggins, Charles R ^a,b  

^a University of Louisville School of Medicine   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN P53; UVOMORULIN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; ENDOCRINE DISEASE; FAMILIAL CANCER; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPARATHYROIDISM; INHERITANCE; MALIGNANT TRANSFORMATION; NEUROENDOCRINE TUMOR; NOTE; ONCOGENE; PEUTZ JEGHERS SYNDROME; PHEOCHROMOCYTOMA; RISK REDUCTION; THYROID MEDULLARY CARCINOMA;

ADULT; BREAST NEOPLASMS; CHILD; ENDOCRINE SYSTEM DISEASES; FEMALE; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE;

EID: 67651151214     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (47)

1. Culler D, Grimes SJ, Acheson LS, et al. Cancer genetics in primary care. Prim Care 2004;31:649-83, xi.
2. American Cancer Society. Cancer Facts and Figures 2006; 2006:1-58.
3. Pharoah PD, Lipscombe JM, Redman KL, et al. Familial predisposition to breast cancer in a British population: Implications for prevention. Eur J Cancer 2000;36:773-9.
4. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
5. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378: 789-92.
6. Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 2007;357: 154-62.
7. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.
8. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-65.
9. American Cancer Society. Cancer Facts and Figures, 2009. 2009:1-59.
10. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
11. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
12. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
13. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89.
14. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345: 159-64.
15. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2004;22:1055-62.
16. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
17. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-21.
18. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-304.
19. Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: A clinical and genetic study in 21 patients. Clin Genet 1986;29:222-33.
20. Uppal S, Mistry D, Coatesworth AP. Cowden disease: A review. Int J Clin Pract 2007;61:645-52.
21. Calva D, Howe JR. Hamartomatous polyposis syndromes. Surg Clin North Am 2008;88:779-817, vii.
22. Li FP, Fraumeni JF Jr.. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71:747-52.
23. Hwang SJ, Lozano G, Amos CI, et al. Germline p53 mutations in a cohort with childhood sarcoma: Sex differences in cancer risk. Am J Hum Genet 2003;72:975-83.
24. Wagner J, Portwine C, Rabin K, et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 1994;86:1707-10.
25. Nusbaum R, Vogel KJ, Ready K. Susceptibility to breast cancer: Hereditary syndromes and low penetrance genes. Breast Dis 2006;27:21-50.
26. Schussheim DH, Skarulis MC, Agarwal SK, et al. Multiple endocrine neoplasia type 1: New clinical and basic findings. Trends Endocrinol Metab 2001;12:173-8.
27. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
28. Wautot V, Vercherat C, Lespinasse J, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: Search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat 2002;20:35-47.
29. Heshmati HM, Hofbauer LC. Multiple endocrine neoplasia type 2: Recent progress in diagnosis and management. Eur J Endocrinol 1997;137:572-8.
30. Machens A, Ukkat J, Brauckhoff M, et al. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005;257:50-9.
31. Machens A, Dralle H. Multiple endocrine neoplasia type 2 and the RET protooncogene: From bedside to bench to bedside. Mol Cell Endocrinol 2006;247:34-40.
32. Wermers RA, Khosla S, Atkinson EJ, et al. The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med 1997;126: 433-40.
33. Uchino S, Noguchi S, Sato M, et al. Screening of the Men1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res 2000;60: 5553-7.
34. Cadiot G, Vuagnat A, Doukhan I, et al. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 1999;116:286-93.
35. Thompson NW. Surgical treatment of the endocrine pancreas and Zollinger-Ellison syndrome in the MEN 1 syndrome. Henry Ford Hosp Med J 1992;40:195-8.
36. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998;243: 495-500.
37. Thompson NW. Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surg Oncol Clin N Am 1998;7:881-91.
38. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88: 1139-48.
39. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore)1984;63:319-42.
40. You YN, Lakhani V, Wells SA Jr, et al. Medullary thyroid cancer. Surg Oncol Clin N Am 2006;15:639-60.
41. Eng C, Mulligan LM, Smith DP, et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995;43:123-7.
42. Rodriguez GJ, Balsalobre MD, Pomares F, et al. Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center. J Am Coll Surg 2002;195:159-66.
43. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42.
44. Sabiston Surgery. 2008. Ref Type: Generic.
45. Eisenhofer G, Keiser H, Friberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998;83:2175-85.
46. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005;23:1656-63.
47. Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol 2005;17:7-12.